Wu YL - Search Results

1

Beyond tissue biopsy: a diagnostic framework to address tumor heterogeneity in lung cancer.

Voigt W, Manegold C, Pilz L, Wu YL, Müllauer L, Pirker R, Filipits M, Niklinski J, Petruzelka L, Prosch H. Voigt W, et al. Among authors: wu yl. Curr Opin Oncol. 2020 Jan;32(1):68-77. doi: 10.1097/CCO.0000000000000598. Curr Opin Oncol. 2020. PMID: 31714259 Review.

2

CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism.

Nie Q, Yang XN, An SJ, Zhang XC, Yang JJ, Zhong WZ, Liao RQ, Chen ZH, Su J, Xie Z, Wu YL. Nie Q, et al. Among authors: wu yl. Eur J Cancer. 2011 Sep;47(13):1962-70. doi: 10.1016/j.ejca.2011.04.018. Epub 2011 May 26. Eur J Cancer. 2011. PMID: 21616658

3

Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.

Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang JJ, Xu CR, Yan HH, Chen HJ, Su J, Zhong WZ, Yang XN, An SJ, Wang BC, Huang YS, Wang Z, Wu YL. Zhou Q, et al. Among authors: wu yl. J Clin Oncol. 2011 Aug 20;29(24):3316-21. doi: 10.1200/JCO.2010.33.3757. Epub 2011 Jul 25. J Clin Oncol. 2011. PMID: 21788562

4

EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas.

Chen ZY, Zhong WZ, Zhang XC, Su J, Yang XN, Chen ZH, Yang JJ, Zhou Q, Yan HH, An SJ, Chen HJ, Jiang BY, Mok TS, Wu YL. Chen ZY, et al. Among authors: wu yl. Oncologist. 2012;17(7):978-85. doi: 10.1634/theoncologist.2011-0385. Epub 2012 Jun 6. Oncologist. 2012. PMID: 22673630 Free PMC article.

5

Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors? - A literature-based meta-analysis.

Xu C, Zhou Q, Wu YL. Xu C, et al. Among authors: wu yl. J Hematol Oncol. 2012 Oct 10;5:62. doi: 10.1186/1756-8722-5-62. J Hematol Oncol. 2012. PMID: 23050865 Free PMC article.

6

Epidermal growth factor receptor inhibition in lung cancer: status 2012.

Hirsch FR, Jänne PA, Eberhardt WE, Cappuzzo F, Thatcher N, Pirker R, Choy H, Kim ES, Paz-Ares L, Gandara DR, Wu YL, Ahn MJ, Mitsudomi T, Shepherd FA, Mok TS. Hirsch FR, et al. Among authors: wu yl. J Thorac Oncol. 2013 Mar;8(3):373-84. doi: 10.1097/JTO.0b013e31827ed0ff. J Thorac Oncol. 2013. PMID: 23370315 Free article. Review.

7

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.

Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, Ladrera G, Srimuninnimit V, Sriuranpong V, Sandoval-Tan J, Zhu Y, Liao M, Zhou C, Pan H, Lee V, Chen YM, Sun Y, Margono B, Fuerte F, Chang GC, Seetalarom K, Wang J, Cheng A, Syahruddin E, Qian X, Ho J, Kurnianda J, Liu HE, Jin K, Truman M, Bara I, Mok T. Wu YL, et al. Lancet Oncol. 2013 Jul;14(8):777-86. doi: 10.1016/S1470-2045(13)70254-7. Epub 2013 Jun 17. Lancet Oncol. 2013. PMID: 23782814 Clinical Trial.

8

The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.

Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crinò L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Pérol M, Smit EF, Syrigos K, van Meerbeeck JP, van Zandwijk N, Yang JC, Zhou C, Vokes E. Manegold C, et al. Among authors: wu yl. J Thorac Oncol. 2017 Feb;12(2):194-207. doi: 10.1016/j.jtho.2016.10.003. Epub 2016 Oct 8. J Thorac Oncol. 2017. PMID: 27729297 Free article. Review.

9

Heterogeneity of the resistance to gefitinib treatment in a non-small cell lung cancer patient with active epidermal growth factor receptor mutation.

Xu CR, Zhong WZ, Zhou Q, Zhang XC, Yang JJ, Wu YL. Xu CR, et al. Among authors: wu yl. Thorac Cancer. 2017 Jan;8(1):51-53. doi: 10.1111/1759-7714.12382. Epub 2016 Nov 1. Thorac Cancer. 2017. PMID: 27801981 Free PMC article.

10

Mixed Responses to Systemic Therapy Revealed Potential Genetic Heterogeneity and Poor Survival in Patients with Non-Small Cell Lung Cancer.

Dong ZY, Zhai HR, Hou QY, Su J, Liu SY, Yan HH, Li YS, Chen ZY, Zhong WZ, Wu YL. Dong ZY, et al. Among authors: wu yl. Oncologist. 2017 Jan;22(1):61-69. doi: 10.1634/theoncologist.2016-0150. Oncologist. 2017. PMID: 28126915 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,376 results

Search Page

Filters